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ABSTRACT 
 
The Orai1 Ca2+ permeable ion channel is an important component of store operated Ca2+ entry (SOCE) in 
cells. It’s over-expression in basal molecular subtype breast cancers has been linked with poor prognosis, 
making it a potential target for drug development. We pharmacologically characterised a number of reported 
inhibitors of SOCE in MDA-MB-231 breast cancer cells using a convenient Fluorescence Imaging Plate 
Reader (FLIPR) assay, and show that the rank order of their potencies in this assay is the same as those 
reported in a wide range of published assays. The assay was also used in a screening project seeking novel 
inhibitors. Following a broad literature survey of classes of calcium channel inhibitors we used simplified 
ligand structures to query the ZINC on-line database, and following two iterations of refinement selected a 
novel Orai1-selective dichlorophenyltriazole hit compound. Analogues of this were synthesized and 
evaluated in the FLIPR assay to develop structure-activity relationships (SAR) for the three domains of the 
hit; triazole (head), dichlorophenyl (body) and substituted phenyl (tail). For this series, the results suggested 
the need for a lipophilic tail domain and an out-of-plane twist between the body and tail domains. 
 
Keywords: Calcium signalling, store-operated calcium entry (SOCE), pharmacological inhibitors, 
pharmacophore modelling, Orai1, breast cancer 
 
Abbreviations: AFU, arbitrary fluorescence units; CPA, cyclopiazonic acid;  [Ca2+]CYT, cytosolic free Ca2+; 
ER, endoplasmic reticulum; FLIPR, Fluorescence Imaging Plate Reader; IP3, inositol trisphophate; PSS, 
physiological salt solution; SAR, structure-activity relationship; SERCA, sarco/endoplasmic reticulum 
ATPase; SOCE, store operated Ca2+ entry; TRP, transient receptor potential 
 
 
1. Introduction 
The regulation of cytosolic free Ca2+ ([Ca2+]CYT)  is a vital component of a variety of cellular signalling 
cascades that are responsible for processes as diverse as muscle contraction to hormone secretion.1 The 
opening of Ca2+ permeable ion channels on the plasma membrane is one of the key mechanisms for 
increasing [Ca2+]CYT.  These Ca2+ permeable ion channels include voltage-gated Ca2+ channels such as L-
type Ca2+ channels which are the target for dihydropyridine-based Ca2+ channel blockers used in the 
treatment of hypertension;2 transient receptor potential (TRP) channels such as the heat sensor TRPV1 
activated by the red hot chilli component capsaicin;3 and the more recently identified component of store 
operated Ca2+ entry (SOCE) - Orai1.  
 
  
SOCE describes the activation of Ca2+ influx through the sensing of depletion of intracellular calcium stores 
of the endoplasmic reticulum.4 Such depletion occurs through the release of Ca2+ by activation of 
phospholipase C coupled G-protein coupled receptors and the associated production of inositol triphosphate 
(IP3) and activation of IP3-activated Ca2+ channels of the endoplasmic reticulum. SOCE can also be induced 
by pharmacological inhibition of the sarco/endoplasmic reticulum ATPase (SERCA), a calcium pump 
responsible for the active transport of Ca2+ into the endoplasmic reticulum.  
 
In 2006, Orai1 was identified as a plasma membrane protein responsible for SOCE.5-7 Orai1 is implicated in 
a variety of physiological functions including processes important in immunity,5 lactation8 and the 
cardiovascular and respiratory systems.9 A number of studies have also linked Orai1 with cancer.10, 11 For 
example, basal molecular subtype breast cancers associated with poor prognosis express elevated levels of 
Orai1 and alterations in the relative levels of the Orai1 activators STIM1 and STIM2.12 Silencing of Orai1 
reduces proliferation and metastasis of breast cancer cells such as MDA-MB-231 basal-like breast cancer 
cells12, 13 and pharmacological inhibition of SOCE has been shown to reduce the proliferation and metastasis 
of MDA-MB-231 breast cancer cells.13, 14 
 
A variety of agents have been reported15, 16 to inhibit SOCE and this pathway has been highlighted as an 
opportunity for therapies for the treatment of a variety of diseases.17  In this study we assessed the effects of 
a number of reported inhibitors of SOCE in MDA-MB-231 breast cancer cells using a Fluorescence Imaging 
Plate Reader (FLIPR), and also report on a novel class of triazole-based SOCE inhibitors. 
 
 
2. Results and Discussion 
 
2.1. Chemistry 
Compounds 14-16 of Table 2 were prepared by K2CO3-induced condensation of iminotriazole 25 and the 
appropriate 2-bromoethoxybenzenes 26-28 (Scheme 1). Aldehyde 20 was similarly prepared from bromide 
26 and aldehyde 29. Aldehyde 29 was also bromoethylated to give bromide 30, which gave the pyridyl 
aldehyde 31 and iminotriazole 17 via (Scheme 2). Finally, the monochloro derivatives 18 and 19 were 
similarly prepared by condensation of bromide 26 with the known iminotriazoles 32 and 33 respectively 
(Scheme 3). Compound structures and purity were monitored by 1H NMR spectroscopy, HPLC and 
combustion analysis. 
 
 
Scheme 1.  Reagents and conditions: (i) K2CO3, dry DMF, 48 h, 20 oC. 
 
 
  
 
 
 
Scheme 2. Reagents and conditions: (i) dibromoethane, K2CO3 ,  dry DMF, 80 oC, 24 h; (ii) pyridin-3-ol, 
K2CO3, dry DMF, 12h, 40 oC; (iii) 4H-1,2,4-triazol-4-amine, MeOH/THF, 5h, reflux; (iv) K2CO3 , dry 
DMF, 48 h, 20 oC. 
 
  
 
 
Scheme 3. Reagents and conditions: (i) K2CO3, dry DMF, 24 h, 20 oC.   
 
 
 
2.2. Biology 
 
Measurement of free intracellular calcium was carried out using a Fluorescence Imaging Plate Reader 
(FLIPR) Ca2+ assay in MDA-MB-231 breast cancer cells (Tables 1 and 2). This assay has been 
demonstrated to be sensitive to changes in Orai1 activity in MDA-MB-23112 and is described in detail in the 
methods section. As shown in Figure 1, addition of the SERCA inhibitor cyclopiazonic acid (CPA, 10 µM) 
produced a gradual release of Ca2+ from internal stores indicated by peak 1. Due to the chelation of 
extracellular Ca2+ ions with the calcium-specific chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid) (BAPTA) this resulted in store depletion. The addition of extracellular Ca2+ produced the 
SOCE (peak 2). This SOCE peak was reduced by silencing of Orai1 but not the related isoforms Orai2 and 
Orai3 (Figure 1A) and the reported SOCE inhibitor YM-58483 (1) (Figure 1B). The assessment of peak 1 
(Ca2+ release) and peak 2 (SOCE) allowed effective and rapid identification of agents which were not 
selective and may have affected SOCE due to a consequence of effects on Ca2+ store levels (equipotent 
against peak 1 and peak 2 (e.g., SKF-96365 (7) and mibefradil (8)) and those able to inhibit SOCE in the 
absence of effects on Ca2+ store release (no effect on peak 1, inhibition of peak 2, e.g. YM-58483 (1) and 
Synta66 (12)). The consistent reporting of peak 1 concentration response effects described in this FLIPR 
assay, represents a powerful tool for the high throughput identification of agents that may alter SOCE 
through mechanisms independent of Orai or STIM proteins. 
 
 
  
 
 
 
Table 1. Evaluation of known calcium channel inhibitors for Orai1 activity 
 
No Structure IC50a 
Concentration Response 
Curve For SOCE 
  ER 
release 
(Peak 1) 
 
SOCE 
(Peak2)  
1 
 
 
not 
activeb 
2.8±0.9
5 
 
2 
 
 
not 
activeb 57±39 
 
  
3 
 
not 
activeb 
not 
activeb  
4 
 
not 
activeb 
not 
activeb  
5 
 
94 ±7.2 17±1.2 
 
6 
 
~100 27±8.4 
 
7 
 
 
 
42±0.4 
 
67± 
11.8 
 
8 
 
 
52.1±2.
5 >100 
 
9 
 
not 
activeb 
not 
activeb  
10c 
 
not 
activeb 
55% at 
30 µM 
(est.)c,d 
 
11c not 
activeb 
not 
activeb  
12 
         
not 
activeb 
not 
activeb  
  
13c 
 
not 
activeb 
1.3±1.8
d
 
 
 
Footnotes for Table 1 
aIC50 is drug concentration for a half-maximal response; bLess than 10% inhibition at 100 µM. cEstimate of 
activity where 100% inhibition not reached. dDue to low solubility, these compounds were tested only up to 
30 µM.  
 
Pyrazole analogues such as YM-58483 (1)18 are known to be potent inhibitors of thapsigargin-induced 
SOCE Ca2+ influx in cells, being 30-fold more selective for SOCE over voltage-gated Ca2+ channels, and 
many analogues are known. Members of the class inhibit hypersensitivity reactions in mice, attributed to 
their inhibition of T-cell activation,19 but also show activity against other Ca2+ channels such as TRPM4.20 
In our assay, 1 was the second most potent inhibitor of SOCE mediated by Orai1, with an IC50 of 2.8 µM, 
and highly selective for Orai1 versus the other channels studied here. The closely-related 21 2 was also active 
against Orai1 but the structurally related compounds 3 and 4, with changes in the pyrazole ring, were not 
active.  None of the compounds were active against TRPV1, TRPM8 or CaV2.2 at concentrations up to 100 
µM (data not shown).  
  
The well-known anti-mycotic imidazole econazole (5) has also been shown to block SOCE by acting 
extracellularly16, 22 and showed measurable Orai1 activity in our assay. The structurally related analogue 
miconazole (6)23 was also active and showed some selectivity for Orai1. SKF-96365 (7), one of the first 
reported SOCE channel inhibitors,24 is known to also prevent tumour metastasis13 but is reported to be 
relatively non-selective, blocking many other ion channels with similar potency.25, 26 Mibefradil (8) is an 
inhibitor of T-type Ca2+ channels,27 and was briefly marketed for migraine, but was withdrawn because of 
drug-drug interactions due to its potent inhibition of CYP3A4.28 In an earlier study29 it was shown to have no 
effect on signal- and extracellular Ca2+-dependent increases in [Ca2+] stimulated by oxytocin. In our assay 
both 7 and 8 were active (albeit not very potent; IC50s 67 and above 100 µM respectively) against Orai1-
mediated Ca2+ influx (Table 1) but were not selective with respect to inhibition of the CaV2.2 channel (data 
not shown).  
YC-1 (9) is a nitric oxide-independent activator of soluble guanylyl cyclase via allosteric binding,30 and is 
reported to be an activator of large-conductance Ca2+-activated potassium channels,31 but was not active in 
our assay. The antifungal drug clotrimazole (10) is structurally similar to the Ca2+-dependent potassium 
Gardos channel inhibitor senicapoc,32 but was similarly not active in our assay. The antifungal drug 
itraconazole (11) is a triazole-based calcium channel inhibitor that has been shown to have anti-angiogenic 
activity, and is in clinical trial for non-small-cell lung cancer,33, 34 but was not active in our assay. 
The urea analogue 12 was the most potent of a number of analogues reported35 as specific inhibitors of 
Orai1, but was not active in our assay. Finally, the extensively-studied biphenyl analogue Synta66 (13)36-38 
has been demonstrated to be a potent (IC50 26 nM by patch-clamp assay) and selective Orai1 inhibitor. This 
was confirmed in the FLIPR assay, where it was the most potent (IC50 1.3 µM) literature compound 
evaluated. These studies with a variety of literature compounds demonstrated the utility of the FLIPR assay 
to rapidly assess the properties of compounds for their effects on Orai1-controlled Ca2+ influx into cells.  
Overall, while there is too much diversity in the assay methods to attempt a quantitative comparison 
between our FLIPR assay results and literature values for these known compounds, the rank order of their 
potencies is certainly the same. The differences in effectiveness of various agents in this model may be 
related to the cell line used, for example Orai1 channels are known to form heteromers with other ion 
channel components and this could lead to differences in sensitivity to various bioactive molecules and 
pharmacological modulators, this is exemplified by the remodeling of Orai1/Orai3 channels in some prostate 
cancer cells which are activated by arachidonic acid rather than Ca2+ store depletion (new ref 39). 
  
The assay was also used in a screening project seeking novel inhibitors. Following a literature survey to 
identify different classes of calcium channel inhibitors of all types, we used either the ligand structures or 
simplified versions as queries for the ZINC on-line database (SI Table 1). The results of the ZINC similarity 
search were combined and reduced to a smaller set of 20 compounds (based on similarity, availability and 
cost) that were subsequently purchased and screened in the FLIPR assay for Orai1-selective effects. From 
this set we discovered two compounds active in our assay; T6454376 and 6035967 (Figure S1) (IC50 values 
estimated at 48 and 75 µM from a single determination). These compounds were used, along with other 
literature compounds that inhibited Orai1-controlled Ca2+ influx in our hands (these included compounds 1, 
2, 5, 7, 8 and 9) to search for related molecules from Chembridge. The results of the search were then 
restricted to either the molecular weight or clogP range of the query compounds, then by availability and 
cost. A final collection of 2140 compounds was tested. A triazole (14) from the final screening library was 
selected as a hit for further elaboration since, although containing both a triazole unit and the 
dichlorobenzene unit of miconazole, it was overall novel and showed encouraging potency and selectivity 
for Orai1 in the FLIPR assay. The ability of FLIPR to simultaneously assess Ca2+ levels in 384 wells over 
the entire experimental period was critical in defining the properties of peak 1 and peak 2 for each tested 
compound, and would not be possible using approaches not capable to complete simultaneous assessment of 
all wells (new ref 40). 
The results of this initial structure-activity relationship (SAR) study are shown in Table 2. For SAR 
purposes, 14 can be divided into three separate domains, defined as the head (triazole), body 
(dichlorophenyl) and tail (substituted phenyl) (Figure 2). The dichloro unit making up the body of the 
compound suggested the existence of an out-of-plane twist in the molecule. Overall, 14 is relatively 
lipophilic (clogP 4.73), with much of the lipophilicity residing in the sec-butyl tail unit. Each of these 
features was investigated.  Substitutions in the tail provided an opportunity to vary the overall lipophilicity 
and perhaps improve solubility. Both the methyl (15) (clogP 3.27) and tert-butyl (16) (clogP 4.60) were 
prepared and showed some selectivity for Orai1 but were much less active than 14, not achieving IC50s 
below 100 µM. In contrast the much more hydrophilic 3-pyridyl analogue 17 (clogP 1.77) was essentially 
inactive.  
 
 
 
Figure 2. Defined structural domains of the triazole class of Orai1 inhibitors (Table 2) 
 
 
Table 2. Evaluation of novel triazoles for Orai1 activity  
 
No 
Structure      IC50a (µM) 
Concentration Response 
Curve For SOCE 
  ER 
release 
(Peak 1) 
 
SOCE 
(Peak2)  
N
N
N
N
Cl
Cl
O
O
HEAD
BODY
TAIL
  
14 
35693 
(lead compound from screen) 
not 
activeb 
96.9±3
2 
 
15 
  
36882 
(analogue of lead) 
not 
activeb 
22% at 
100 µM 
(est.)c 
 
16 
 
SN36959 (more lipophilic)) 
not 
activeb 
11% at 
100 µM 
(est.)c 
 
17 
 
not 
activeb 
not 
activeb  
18 
 
not 
activeb 
not 
activeb  
19 
 
not 
activeb 
22% at 
100 µM 
(est.)c 
 
20 
 
not 
activeb 
not 
activeb  
21c 
 
~100 
 
~100 
 
 
Footnotes for Table 2 
aIC50 is drug concentration for a half-maximal response; bLess than 10% inhibition at 100 µM. cEstimate of 
activity where 100% inhibition not reached.  
 
To explore the influence of the chloride substituents in the central ring, both of the monochloro analogues 
(18 and 19) of the hit compound 14 were prepared and evaluated. Removal of the 3-Cl group ortho to the 
side chain in compound 18 completely abolished activity, whereas the 5-Cl analogue 19 did retain some 
  
activity (albeit at >100 µM), suggesting the requirement of an out-of-plane twist between the body and tail 
domains.  
 
N-benzylidene-4H-1,2,4-triazol-4-amines such as 14 have been reported and evaluated in various biological 
assays,41 but they have potential susceptibility for acid hydrolysis to the corresponding aldehydes. The 
stability of 14 was therefore determined under the conditions used in the calcium influx assay, and no loss of 
compound or formation of the corresponding aldehyde (20) was seen, indicating that hydrolysis is not 
occurring under the FLIPR test conditions. This aldehyde itself was also inactive when tested at two 
concentration points, suggesting that the 4-formimidoyl triazole head group is necessary for the inhibition of 
Orai1 channel activity, but was extremely lipophilic (clogP 6.74). We therefore also explored the more 
hydrophilic aldehyde 21 (clogP 3.79), which significantly inhibited both calcium influx peaks, suggesting 
non-selective activity at multiple targets.  
 
Compound 21 was explored because aromatic aldehydes have been previously evaluated as drugs (Figure 3); 
examples include 22, which inhibits the endoplasmic reticulum transmembrane protein IRE1 (that mediates 
the unfolded protein response) by forming an unusually stable Schiff base with lysine 907.42 Similarly, 
aldehyde MKC-3946 (23) showed growth inhibition in multiple myeloma cell lines and potentiated the 
cytotoxicity of the endoplasmic reticulum stress inducers bortezomib or 17-AAG,43 and 24, which by 
targeting IRE1 mimicked XBP-1 deficiency, suppressed growth of B cell chronic lymphocytic leukemia in a 
xenograft model.44  
 
The compounds in Table 2 were also screened in the FLIPR assay for their ability to inhibit the TRPV1, 
TRMP8 and CaV2.2 (N-type) calcium channels, but none showed any activity up to 100 µM. 
 
 
Figure 3. Literature examples of aromatic aldehyde drugs  
 
2.4. Conclusions 
This study explored the use of a FLIPR Ca2+ assay in MDA-MB-231 breast cancer cells to evaluate a 
number of compounds previously reported (using a variety of different assays) as inhibitors of SOCE 
mediated by Orai1. We also used the assay to briefly explore the SAR around a class of triazoles as potential 
inhibitors. Screening studies had identified the triazole 14 as a novel inhibitor of SOCE (Figure 4A) with 
superior ability to avoid the effects on Ca2+ store release compared with the SOCE inhibitor SKF-96365 (7) 
(Figure 4B) and with a similar inhibition profile (although with slightly less potency) to the SOCE inhibitor 
YM-58683 (1) (Figure 4C). Structure-activity studies suggested that a lipophilic tail unit (Figure 2) was 
needed (compare 14 and 17), with a central unit that provided some non-planarity (compare monochlorides 
18 and 19). Finally, while the free aldehyde (20) of the parent compound was inactive, the aldehyde (21) of 
the (inactive) 3-pyridyl derivative (17) did show activity but was not selective for effects on SOCE (peak 2) 
versus release of Ca2+ from internal stores (peak 1).  
 
  
 
 
3. Experimental  
 
3.1. Chemistry 
 
Final products were analysed by reverse-phase HPLC (Alltima C18 5 µm column, 150 × 3.2 mm; Alltech 
Associated, Inc., Deerfield, IL) using an Agilent HP1100 equipped with a diode-array detector. Mobile 
phases were gradients of 80% CH3CN/20% H2O (v/v) in 45 mM NH4HCO2 at pH 3.5 and 0.5 mL/min. 
Purity was determined by monitoring at 330 ± 50 nm and was ≥95% for all final products. Final product 
purity and structure were also assessed by combustion analysis carried out in the Campbell Microanalytical 
Laboratory, University of Otago, Dunedin, New Zealand. Melting points were determined on an 
Electrothermal 9100 melting point apparatus. NMR spectra were obtained on a Bruker Avance 400 
spectrometer at 400 MHz for 1H. 
 
3.1.1. (E)-1-(2-(2-(4-(sec-Butyl)phenoxy)ethoxy)-3,5-dichlorophenyl)-N-(4H-1,2,4-triazol-4-
yl)methanimine (14) (Scheme 1). A mixture of (E)-2-(((4H-1,2,4-triazol-4-yl)imino)methyl)-4,6-
  
dichlorophenol45 (25) (100 mg, 0.39 mmol) and 1-(2-bromoethoxy)-4-(sec-butyl)benzene44*46 (26) (120 mg, 
0.47 mmol) and K2CO3 (160 mg, 1.17 mmol) were stirred in dry DMF (2 mL) for 48 h. EtOAc was added 
and the system was washed with water and dried (Na2SO4). Flash chromatography (petroleum ether/EtOAc; 
1:1) followed by petroleum ether then Et2O trituration gave 14 (32 mg, 19%) as a white solid; mp 109-110 
oC; 1H NMR (CDCl3) δ 9.04 (s, 1Η), 8.40 (s, 2Η), 7.97 (d, J = 2.6 Hz, 1H), 7.58 (d, J = 2.6 Hz, 1H), 7.09 (d, 
J = 8.6 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 4.50 (dt, J = 4.1, 2.0 Hz, 2H), 4.28 (dt, J = 4.1, 2.0 Hz, 2H), 2.54 
(sext, J = 7.0 Hz, 1H), 1.53 (quint, J = 7.3 Hz, 2H), 1.20 (d, J = 7.0 Hz, 3H), 0.80 (d, J = 7.4 Hz, 3H); Anal. 
Calcd for C21H22Cl2N4O2: C, 58.21; H, 5.12; N, 12.93. Found: C, 58.48; H, 5.18; N, 12.87. 
 
3.1.2. (E)-1-(3,5-Dichloro-2-(2-(p-tolyloxy)ethoxy)phenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (15). 
Similar reaction of 25  (100 mg, 0.39 mmol) and 1-(2-bromoethoxy)-4-methylbenzene47 (27) (100 mg, 0.47 
mmol) and K2CO3 (160 mg, 1.17 mmol) in dry DMF (2 mL) for 24 h, followed by workup, flash 
chromatography (CH2Cl2/MeOH; 100:0 then 197:3) and recrystallization (CH2Cl2/i-Pr2O) gave 15 (48 mg, 
32%) as a white solid; mp 144-145 oC; 1H NMR (CDCl3) δ 9.01 (s, 1H), 8.37 (s, 2H), 7.97 (d, J = 2.6 Hz, 
1H), 7.58 (d, J = 2.6 Hz, 1H), 7.07 (d, J = 8.2 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 4.50 (dt, J = 4.0, 1.9 Hz, 
2H), 4.27 (dt, J = 4.0, 1.9 Hz, 2H), 2.80 (s, 3H). Anal. Calcd for C18H16Cl2N4O2: C, 55.26; H, 4.12; N, 
14.32. Found: C, 55.16; H, 4.09; N, 14.17. 
 
3.1.3.  (E)-1-(2-(2-(4-(tert-Butyl)phenoxy)ethoxy)-3,5-dichlorophenyl)-N-(4H-1,2,4-triazol-4-
yl)methanimine (16). Similar reaction of 25 (300 mg, 1.17 mmol), 1-(2-bromoethoxy)-4-(tert-
butyl)benzene48 (28) (360 mg, 1.40 mmol) and K2CO3 (480 mg, 3.50 mmol) were stirred in dry DMF (3 mL) 
for 24 h. EtOAc was added and the system was washed with water, brine and dried (Na2SO4). Flash 
chromatography (petroleum ether/EtOAc; 1:1 to 2:3) followed by recrystallization (CH2Cl2/i-Pr2O) gave 16 
(63 mg, 13%) as a white solid; mp 85-87 oC; 1H NMR (CDCl3) δ 9.03 (s, 1H), 8.38 (s, 2H), 7.98 (d, J = 2.6 
Hz, 1H), 7.58 (d, J = 2.6 Hz, 1H), 7.29 (d, J = 8.9 Hz, 2H), 6.77 (d, J = 8.9 Hz, 2H), 4.51 (dt, J = 4.0, 1.9 
Hz, 2H), 4.28 (dt, J = 4.0, 1.9 Hz, 2H), 1.29 (s, 9H). Anal. calcd. for C21H22Cl2N4O2: C, 58.21; H, 5.12; N, 
12.93. Found: C, 58.55; H, 5.10; N, 12.65.  
 
3.1.4. (E)-1-(3,5-Dichloro-2-(2-(pyridin-3-yloxy)ethoxy)phenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine 
(17) (Scheme 2). A mixture of 3,5-dichloro-2-hydroxybenzaldehyde (29) (3.0 g, 15.7 mmol) and K2CO3 
(10.8 g, 78.5 mmol) in 1,2 dibromoethane (15 mL) and DMF (5 mL) was heated to 80 oC for 24 h. EtOAc 
was added and the system was washed with water and dried (Na2SO4). Flash chromatography (petroleum 
ether/EtOAc; 100:0 then 99:1) gave 2-(2-bromoethoxy)-3,5-dichlorobenzaldehyde (30) (3.9 g, 83%) as a 
white solid; mp 58-60 oC; 1H NMR (CDCl3) δ 10.45 (s, 1H), 7.73 (d, J = 2.6 Hz, 1H), 7.63 (d, J = 2.7 Hz, 
1H), 4.45 (t, J = 5.7 Hz, 2H), 3.72 (t, J = 5.7 Hz, 2H). Anal. calcd. for C9H7BrCl2O2: C, 36.28; H, 2.37. 
Found: C, 36.34; H, 2.31. 
 
A mixture of 30 (200 mg, 0.67 mmol), pyridin-3-ol (77 mg, 0.81 mmol) and K2CO3 (280 mg, 2.02 mmol) 
were stirred in dry DMF (10 mL) at 40 oC for 12 h. EtOAc was added and the system was washed with 
water, brine and dried (Na2SO4). Flash chromatography (petroleum ether/EtOAc; 1:1 to 2:3) gave 3,5-
dichloro-2-(2-(pyridin-3-yloxy)ethoxy)benzaldehyde (31) (96 mg) as a white solid; 1H NMR (CDCl3) δ 
10.42 (s, 1H), 8.33 (d, J = 2.5 Hz, 1H), 8.27 (dd, J = 4.3, 1.5 Hz, 1H), 7.74 (d, J = 2.6 Hz, 1H), 7.64 (d, J = 
2.6 Hz, 1H), 7.27-7.19 (m, 2H), 4.53 (dt, J = 4.2, 2.4 Hz, 2H), 4.40 (dt, J = 4.2, 2.4 Hz, 2H). The HCl salt 
was prepared by stirring 30 mg of the free base in HCl/MeOH (1.25 M, 2 mL) and CHCl3 (1 mL) for 2 h and 
filtration of the precipitate of 31.HCl  as a white solid; mp 182-184 oC; Anal. calcd. for C14H12Cl3NO3: C, 
48.24; H, 3.47; N, 4.02. Found: C, 48.52; H, 3.38; N, 4.02. 
 
A solution of aldehyde 31 (32 mg, 0.10 mmol) and 4H-1,2,4-triazol-4-amine (9 mg, 0.10 mmol) in MeOH (2 
mL) and THF (1 drop) was heated under reflux for 5 h. After cooling, solvents were removed and residue 
was subjected to flash chromatography (CH2Cl2/MeOH; 100:0 to 93:7) to give 17 (31 mg, 80%) as a white 
solid; mp 149-152 oC; 1H NMR (CDCl3) δ 9.01 (s, 1H), 8.52 (s, 2H), 8.34 (s, 1H), 8.30 (d, J = 4.2 Hz, 1H), 
7.98 (d, J = 2.5 Hz, 1H), 7.60 (d, J = 2.5 Hz, 1H), 7.29-7.16 (m, 2H), 4.58-4.49 (m, 2H), 4.48-4.37 (m, 2H). 
Anal. calcd. for C16H13Cl2N5O2⋅H2O: C, 48.50; H, 3.82; N, 17.68. Found: C, 48.10; H, 3.64; N, 17.66.  
 
3.1.5. 2-(2-(4-(sec-Butyl)phenoxy)ethoxy)-3,5-dichlorobenzaldehyde (20) (Scheme 2). A mixture of 3,5-
dichloro-2-hydroxybenzaldehyde (29) (200 mg, 1.05 mmol), bromide 26 (320 mg, 1.26 mmol) and K2CO3 
  
(430 mg, 3.14 mmol) were stirred in dry DMF (2 mL) for 48 h. EtOAc was added and the system was 
washed with water, brine and dried (Na2SO4). Flash chromatography (petroleum ether/EtOAc; 100:0 to 
99:1) gave 20 (70 mg, 18%) as a white solid; mp 73-74 oC; 1H NMR (CDCl3) δ 10.45 (s, 1H), 7.74 (d, J = 
2.6 Hz, 1H), 7.62 (d, J = 2.6 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 4.51 (dt, J = 4.3, 2.7 
Hz, 2H), 4.31 (dt, J = 4.3, 2.7 Hz, 2H), 2.54 (sext, J = 7.0 Hz, 1H), 1.55 (quint, J = 7.4 Hz, 2H), 1.21 (d, J = 
7.0 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H). Anal. calcd. for C19H20Cl2O3: C, 62.14; H, 5.49. Found: C, 62.20; H, 
5.60.   
 
 3.1.6. (E)-1-(2-(2-(4-(sec-Butyl)phenoxy)ethoxy)-5-chlorophenyl)-N-(4H-1,2,4-triazol-4-
yl)methanimine (18) (Scheme 3). A mixture of (E)-2-(((4H-1,2,4-triazol-4-yl)imino)methyl)-4-
chlorophenol49 (32) (100 mg, 0.45 mmol), bromide 26 (140 mg, 0.54 mmol) and K2CO3 (190 mg, 1.35 
mmol) were stirred in dry DMF (2 mL) for 24 h. EtOAc was added and the system was washed with water, 
brine and dried (Na2SO4). Flash chromatography (CH2Cl2/MeOH; 100:0 then 197:3) followed by 
recrystallization (EtOAc /petroleum ether) gave 18 (110 mg, 61%) as a white solid; mp 127-128 oC; 1H 
NMR (CDCl3) δ 8.91 (s, 1Η), 8.52 (s, 2Η), 8.02 (d, J = 2.7 Hz, 1H), 7.47 (dd, J = 8.9, 2.7 Hz, 1H), 7.12 (d, J 
= 8.6 Hz, 2H), 7.02 (d, J = 8.9 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 4.44 (dt, J = 4.8, 2.6 Hz, 2H), 4.33 (dt, J = 
4.8, 2.6 Hz, 2H), 2.56 (sext, J = 7.0 Hz, 1H), 1.56 (quint, J = 7.3 Hz, 2H), 1.21 (d, J = 6.9 Hz, 3H), 0.81 (d, J 
= 7.4 Hz, 3H). Anal. calcd. for C21H23ClN4O2: C, 63.23; H, 5.81; N, 14.05. Found: C, 63.26; H, 5.69; N, 
14.10. 
 
3.1.7.  (E)-1-(2-(2-(4-(sec-Butyl)phenoxy)ethoxy)-3-chlorophenyl)-N-(4H-1,2,4-triazol-4-
yl)methanimine (19) (Scheme 3). A mixture of E)-2-(((4H-1,2,4-triazol-4-yl)imino)methyl)-2-
chlorophenol50 (33) (100 mg, 0.45 mmol), bromide 26 (140 mg, 0.54 mmol) and K2CO3 (190 mg, 1.35 
mmol) were stirred in dry DMF (2 mL) for 48 h. EtOAc was added and the system was filtered, washed with 
water, brine and dried (Na2SO4). Recrystallization (CH2Cl2/i-Pr2O) gave  (70 mg, 39%) as a white solid; mp 
102-103 oC; 1H NMR (CDCl3) δ 9.13 (s, 1Η), 8.42 (s, 2Η), 8.00 (dd, J = 7.9, 1.6 Hz, 1H), 7.59 (dd, J = 7.9, 
1.6 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.7 Hz, 2H), 4.52 (dt, J = 4.0, 2.0 
Hz, 2H), 4.29 (dt, J = 4.0, 2.0 Hz, 2H), 2.54 (sext, J = 7.0 Hz, 1H), 1.54 (quint, J = 7.3 Hz, 2H), 1.21 (d, J = 
7.0 Hz, 3H), 0.81 (d, J = 7.3 Hz, 3H). Anal. calcd. for C21H23ClN4O2: C, 63.23; H, 5.81; N, 14.05. Found: C, 
63.30; H, 5.73; N, 14.01. 
 
 
3.2 Biology 
 
3.2.1. Compound library development 
A ligand based virtual screening approach was used in two phases for the discovery of SOCE channel 
inhibitors. Initially, known inhibitors where extracted from the literature, including patents, and were either 
kept as the complete molecule or reduced to a core scaffold, and used to query the ZINC on-line compound 
database51 using the similarity search facility. The ligand structures and search query are listed in 
Supplementary Information Table 1. A small virtual library was created by combination of the hit lists for 
each compound and removal of duplicates using the ligand preparation module implemented in SYBYL. 
DIVERSE SOLUTIONS (v6.3.2) was then used to reduce the set size from 675 compounds down to 57. 
This involved calculating a binary fingerprint for each compound using the 166 MACCS keys option, 
comparing these using the Hamming distance calculation method, and selecting the final subset using the 
elimination method option. This smaller set was queried against the ZINC database to find ,suppliers, and a 
final set of 32 compounds was selected, of these 20 were purchased and tested. In the second round, the 
known SOCE channel blockers 1, 2, 5, 7, 8, and 9 along with active molecules identified from the first round 
(T6454376, Enamine; 6035967, Chembridge)   were used to build a larger library of approximately 2140 
compounds from Chembridge. This involved collecting sets of at least 1000 but up to 1316 compounds from 
the Hit2lead on-line vendor (www.hit2lead.com) by submitting each compound to the similarity search tool. 
The hit lists were combined and duplicates were removed using the ligand preparation module within 
SYBYL, leaving a set of 8468 compounds. Reduction of this set was performed firstly by selecting 
compounds that fell within either the molecular weight range (304 to 478) or the clogP range (3.3 to 6.2) of 
the query compounds as calculated in SYBYL. The combined, non-redundant set had 7197compounds that 
occupied a MW range 186.25 to 667.62 and clogP range -3.65 to 9.15, from this a set of 2140 compounds 
occupying a MW range 214.3 to 667.62 and clogP range -1.79 to 9.15 were selected based on cost and 
  
availability. The screening cascade used the primary, medium throughput (96-well plate format) (FLIPR) 
assay,50 50for measuring store operated calcium influx in the basal like breast cancer cell line MDA-MB-
231.  
 
 
3.2.2. Measurement of intracellular free Ca2+ by FLIPR assay 
MDA-MB-231 triple negative breast cancer cells were plated at a density of 2 x 103 cells per well in 384-
well black plates (Corning Costar, Cambridge, MA, USA). Three days post seeding, intracellular free Ca2+ 
levels were measured in a Fluorescence Imaging Plate Reader (FLIPRTETRA, Molecular Devices, Sunnyvale, 
CA, USA) using the PBX Calcium Assay Kit (640175, BD Biosciences, Franklin Lakes, NJ, USA) as 
described previously.52 Briefly, cells were first loaded for 1 hour at 37°C with a dye-loading solution 
comprising of 2 µM PBX Calcium Assay dye, 5% (v/v) PBX Signal Enhancer and 500 µM probenecid in 
physiological salt solution (PSS, 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4, 5 mM 
NaHCO3, 140 mM NaCl, 11.5 mM glucose, pH 7.3). Cells were then treated for 15 min at room temperature 
with different concentrations of compound in a solution containing 5% (v/v) PBX Signal Enhancer and 500 
µM probenecid in PSS. For assessment of store-operated Ca2+ entry (SOCE), which has been previously 
shown to be mediated by Orai1 proteins in MDA-MB-231 cells,12  the following solutions in PSS were 
added in order inside the FLIPRTETRA using a robotic arm: 500 µM BAPTA (Invitrogen, Carlsbad, CA, 
USA) for chelation of extracellular Ca2+; 10 µM cyclopiazonic acid (CPA; Sigma-Aldrich, St Louis, MO) 
for inhibition of sarco/endoplasmic reticulum Ca2+-ATPases (SERCA) pump and depletion of endoplasmic 
reticulum (ER);53 0.5 mM CaCl2 (700 s after the addition of CPA) for assessment of store-operated Ca2+ 
influx. Fluorescence was measured at 470-495 nm excitation and 515-575 nm emission. ScreenWorks 
Software (v2.0.0.27, Molecular Devices) was used for data analyses. Ca2+ levels were assessed through the 
change in relative fluorescence of the Ca2+ dye. The percentage inhibition of the maximum peak height for 
each concentration of each compound normalized to its corresponding DMSO control was calculated and 
plotted separately for peak 1 (a measure of the release of endoplasmic reticulum calcium store) by addition 
of CPA to assess potential non-specific effects on Ca2+ homeostasis and peak 2 (a measure of store-operated 
Ca2+ influx).35,54 Where the % inhibition of peak 2 (SOCE) did not exceed 10% at 100 µM in initial 
assessments, these compounds were defined as not active. 
 
3.2.3. Selectivity screen  
TRPV1 and TRPM8 responses were assessed in HEK293 cells (American Tissue Culture Collection, 
Manassas, VA, USA) 48 h after transfection with plasmid DNA of rTRPV1 (D. Julius, Department of 
Physiology, University of California, Berkeley, CA, USA) or rTRPM8 (K. Zimmermann, Department of 
Anesthesiology, Friedrich-Alexander-University, Erlangen-Nuremberg, Erlangen, Germany) using 
Lipofectamine 2000 as previously described.55 CaV2.2 responses were assessed in SH-SY5Y neuroblastoma 
cells in the presence of nifedipine (10 µM) according to established protocols.56 HEK293 cells were 
routinely maintained in DMEM containing 10% foetal bovine serum, 2 mM L-glutamine, pyridoxine and 
110 mg/ml sodium pyruvate. SH-SY5Y cells (European Collection of Authenticated Cell Cultures, 
Salisbury, UK) were cultured in RPMI 1640 antibiotic-free medium (Invitrogen) supplemented with 10% 
heat-inactivated FBS and 2 mM GlutaMAX™ (Invitrogen). Cells were split every 3-6 days in a ratio of 1:5 
using 0.25% trypsin/EDTA. Cells were plated on 384-well black-walled imaging plates (Corning) at a 
density of 10,000 cells/well (HEK293) or 50,000 cells/well (SH-SY5Y) and used for Ca2+ experiments 
24 hours after plating.  
 
Growth media was removed and replaced with 20 µl/well Calcium 4 No-Wash dye diluted according to the 
manufacturer’s instructions in physiological salt solution (PSS;  NaCl 140 mM, glucose 11.5 mM, KCl 5.9 
mM, MgCl2 1.4 mM, NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 1.8 mM, HEPES 10 mM) and incubated for 
30 min at 37°C/5% CO2. Ca2+ responses were measured using a FLIPRTETRA (Molecular Devices, 
Sunnyvale, CA, USA) fluorescent plate reader with excitation at 470-495 nM and emission at 515-575 nM. 
Camera gain and intensity were adjusted for each plate to yield a minimum of 1500-2000 arbitrary 
fluorescence units (AFU) baseline fluorescence. Test compounds were added 300 s prior to stimulation with 
capsaicin (100 nM; TRPV1), menthol (100 µM, TRPM8) and KCl (90 mM)/CaCl2 (5 mM; CaV2.2). Data 
was analysed using Screenworks 3.2 and FLIPRTETRA data was plotted using GraphPad PrismTM software 
(Version 6.00). 
  
 
 
3.2.4. Determination of the stability of 14 under simulated conditions of the FLIPR assay 
 
Probenecid (714 mg, 2.50 mmol) was placed in a 50 mL graduated cylinder. Portions of 1 M NaOH (50 µL) 
were added till all probenecid dissolved. Water (5 mL) was added and pH adjusted to 7.4 with HCl giving a 
total volume of 10 mL. Compound 14 (1.08 mg, 2.4 µmol) was dissolved in DMSO (25 µL). The solution 
was allowed to stand at room temperature for 25 min. A portion (0.9 µL) of this solution was added to 
phosphate-buffered saline (300 µL, pH 7.4), followed by addition of a portion (20 µL) of the probenecid 
solution and the mixture was allowed to stand at room temperature for 1 h. A portion of this solution was 
then subjected to HPLC analysis on a Zorbax Eclipse XDB C8, 5u, 4.6 x 150 mm column, using a flow rate 
of 1.2 mL/min and a gradient of water and MeCN as follows: 30% - 100% MeCN over 18 min, then 100% - 
30% MeCN over 2 min, followed by 30%MeCN post run over 3 min.  Compound 20 (0.91 mg, 2.4 µmol) 
was dissolved in DMSO (25 µL). A portion (0.9 µL) of this solution was added to DMSO (320 µL) to be 
used as a standard for the detection of any hydrolysis of 14 to 20. 
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Highlights 
• A fluorescence imaging plate reader assay for calcium channel inhibitors 
 
• Inhibitors of the Orai1 SOCE Ca2+ channel that do not affect Ca2+ store release 
 
• Similarity-based screening assay to identify triazole-based Orai1 inhibitors 
 
